INAB Quote, Financials, Valuation and Earnings

Genprex has a net margin of -- compared to IN8bio's net margin of --. IN8bio's return on equity of -- beat Genprex's return on equity of --.

IN8bio has a consensus price target of $4.75, signalling upside risk potential of 1503.65%. On the other hand Genprex has an analysts' consensus of $7.50 which suggests that it could grow by 941.67%. Given that IN8bio has higher upside potential than Genprex, analysts believe IN8bio is more attractive than Genprex.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex has a beta of -1.302, suggesting its less volatile than the S&P 500 by 230.243%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. Genprex pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than Genprex quarterly revenues of --. IN8bio's net income of -$7.1M is lower than Genprex's net income of -$4.3M. Notably, IN8bio's price-to-earnings ratio is -- while Genprex's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus -- for Genprex. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to IN8bio's net margin of -49.65%. IN8bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IN8bio has a consensus price target of $4.75, signalling upside risk potential of 1503.65%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 408.46%. Given that IN8bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe IN8bio is more attractive than NovaBay Pharmaceuticals.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IN8bio's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IN8bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to IN8bio's net margin of -2357.27%. IN8bio's return on equity of -- beat Palatin Technologies's return on equity of --.

IN8bio has a consensus price target of $4.75, signalling upside risk potential of 1503.65%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1503.77%. Given that Palatin Technologies has higher upside potential than IN8bio, analysts believe Palatin Technologies is more attractive than IN8bio.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. IN8bio's net income of -$7.1M is higher than Palatin Technologies's net income of -$7.8M. Notably, IN8bio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sensei Biotherapeutics has a net margin of -- compared to IN8bio's net margin of --. IN8bio's return on equity of -- beat Sensei Biotherapeutics's return on equity of --.

IN8bio has a consensus price target of $4.75, signalling upside risk potential of 1503.65%. On the other hand Sensei Biotherapeutics has an analysts' consensus of $4.13 which suggests that it could grow by 631.13%. Given that IN8bio has higher upside potential than Sensei Biotherapeutics, analysts believe IN8bio is more attractive than Sensei Biotherapeutics.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sensei Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensei Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. Sensei Biotherapeutics pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than Sensei Biotherapeutics quarterly revenues of --. IN8bio's net income of -$7.1M is higher than Sensei Biotherapeutics's net income of -$7.3M. Notably, IN8bio's price-to-earnings ratio is -- while Sensei Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus -- for Sensei Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.